Sugammadex Piramal

Authorised

This medicine is authorised for use in the European Union

sugammadex

Overview

Sugammadex Piramal is a medicine used to reverse the effect of the muscle relaxants rocuronium and vecuronium. Muscle relaxants are medicines used during some types of operation to make the muscles relax, including the muscles that help the patient to breathe. Muscle relaxants make it easier for the surgeon to do the operation. Sugammadex Piramal is used to speed up the recovery from the muscle relaxant, usually at the end of the operation.

Sugammadex Piramal can be used in adults who have received rocuronium and vecuronium, and in children from birth who have received rocuronium.

Sugammadex Piramal contains the active substance sugammadex and is a ‘generic medicine’. This means that Sugammadex Piramal contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Sugammadex Piramal is Bridion. For more information on generic medicines, see the question-and-answer document here.

How is Sugammadex Piramal used?

Sugammadex Piramal can only be obtained with a prescription. It is given by or under the supervision of an anaesthetist (a doctor specialised in anaesthesia). Sugammadex Piramal is given into a vein as a single bolus injection (given all at once).

For more information about using Sugammadex Piramal, see the package leaflet or contact your doctor or pharmacist.

How does Sugammadex Piramal work?

The active substance in Sugammadex Piramal, sugammadex, attaches to the muscle relaxants rocuronium and vecuronium, stopping them from having an effect. As a result, the muscles contract and begin to work normally again, including the muscles that help the patient to breathe.

How has Sugammadex Piramal been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Bridion, and do not need to be repeated for Sugammadex Piramal.

As for every medicine, the company provided studies on the quality of Sugammadex Piramal. There was no need for ‘bioequivalence’ studies to investigate whether Sugammadex Piramal is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Sugammadex Piramal is given by injection into a vein, so the active substance is delivered straight into the bloodstream.

What are the benefits and risks of Sugammadex Piramal?

Because Sugammadex Piramal is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Why is Sugammadex Piramal authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sugammadex Piramal has been shown to be comparable to Bridion. Therefore, the Agency’s view was that, as for Bridion, the benefits of Sugammadex Piramal outweigh the identified risks and it can be authorised for use in the EU.

What measures are being taken to ensure the safe and effective use of Sugammadex Piramal?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sugammadex Piramal have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sugammadex Piramal are continuously monitored. Suspected side effects reported with Sugammadex Piramal are carefully evaluated and any necessary action taken to protect patients.

Other information about Sugammadex Piramal

Sugammadex Piramal received a marketing authorisation valid throughout the EU on 23 June 2023.

Sugammadex Piramal : EPAR - Medicine Overview

Adopted Reference Number: EMADOC-1829012207-24014

Sugammadex Piramal : EPAR - Risk management plan summary

Product information

Sugammadex Piramal : EPAR - Product Information

Sugammadex Piramal : EPAR - All authorised presentations

Product details

• Name of medicine:
  Sugammadex Piramal
• Active substance:
  sugammadex sodium
• International non-proprietary name (INN) or common name:
  sugammadex
• Therapeutic area (MeSH):
  Neuromuscular Blockade
• Anatomical therapeutic chemical (ATC) code:
  V03AB35

Pharmacotherapeutic group

sugammadex

Therapeutic indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in paediatric patients from birth to 17 years.

Authorisation details

• EMA product number:
  EMEA/H/C/006083
• Generic:

  This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

• Marketing authorisation holder:
  Piramal Critical Care B.V.

  Rouboslaan 32; 2252 TR Voorschoten; Netehrlands

• Opinion adopted:
  26/04/2023
• Marketing authorisation issued:
  23/06/2023
• Revision:
  3

Assessment history

Changes since initial authorisation of medicine

Sugammadex Piramal: EPAR - Procedural steps taken and scientific information after authorisation

Sugammadex Piramal: EPAR - Procedural steps taken and scientific information after authorisation (archive)

Initial marketing authorisation documents

Sugammadex Piramal : EPAR - Public Assessment Report

Adopted Reference Number: EMA/228402/2023

CHMP summary of positive opinion for Sugammadex Piramal

Adopted Reference Number: EMA/CHMP/178271/2023